[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100592634":3},{"organization":4,"outcomesModule":7,"designInfo":18,"detailedDescription":24,"studyPopulation":17,"armGroups":25,"interventions":37,"overallOfficials":46,"centralContacts":50,"locations":59,"responsibleParty":77,"collaborators":17,"id":79,"slug":17,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":17,"eligibilityCriteria":83,"healthyVolunteers":84,"sex":85,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":17,"studyType":91,"phases":92,"briefSummary":94,"conditions":95,"keywords":17,"overallStatus":62,"whyStopped":17,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"First Affiliated Hospital of Fujian Medical University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":17},[9],{"measure":10,"description":11,"timeFrame":12},"SUV of tumors","Compare the SUV of tumors between 68Ga-dPNE PET\u002FCT and 18F-FDG PET\u002FCT.","Through study completion, an average of 3 months",[14],{"measure":15,"description":16,"timeFrame":12},"Diagnostic value","Sensitivity and specificity of 68Ga-dPNE in patients with various types of cancer and compare it with 18F-FDG PET\u002FCT.",null,{"allocation":19,"interventionModel":20,"interventionModelDescription":17,"primaryPurpose":21,"observationalModel":17,"timePerspective":17,"maskingInfo":22},"RANDOMIZED","PARALLEL","DIAGNOSTIC",{"masking":23,"maskingDescription":17,"whoMasked":17},"NONE","The boom in radiopharmaceuticals continues to persist, including their driving effects in the field of immunotherapy. CD73 (ecto-5'-nucleotidase), a key purine metabolic enzyme, catalyzes the conversion of extracellular nucleotides to adenosine, promoting tumor immune evasion and unfavorable clinical outcomes. Notably, CD73 is highly expressed in 74.3% of breast cancer cases, with its prevalence exceeding 45% in liver, gastric, colorectal, and ovarian cancers. As a new CD73-targeted PET radiotracer, 68Ga-dPNE, is promising as an excellent imaging agent applicable to various cancers. The present study aimed to evaluate the biodistribution, pharmacokinetics, and dosimetry of 68Ga-dPNE, and performed a head-to-head comparison with 18F-FDG PET\u002FCT scans in patients with various cancers.",[26,32],{"label":27,"type":28,"description":29,"interventionNames":30},"68Ga-dPNE PET\u002FCT","EXPERIMENTAL","Intravenous injection of 68Ga-dPNE. 68Ga-dPNE PET\u002FCT will be used to detect tumors.",[31],"Drug: 68Ga-dPNE",{"label":33,"type":28,"description":34,"interventionNames":35},"18F-FDG PET\u002FCT","Intravenous injection of 18F-FDG. 18F-FDG PET\u002FCT will be used to detect tumors.",[36],"Drug: 18F-FDG",[38,42],{"type":39,"name":40,"description":29,"armGroupLabels":41,"otherNames":17},"DRUG","68Ga-dPNE",[27],{"type":39,"name":43,"description":44,"armGroupLabels":45,"otherNames":17},"18F-FDG","Intravenous injection of 18F-FDG.18F-FDG PET\u002FCT will be used to detect tumors.",[33],[47],{"name":48,"affiliation":5,"role":49},"Weibing Miao, MD","PRINCIPAL_INVESTIGATOR",[51,55],{"name":48,"role":52,"phone":53,"phoneExt":17,"email":54},"CONTACT","+86-0591-87981618","miaoweibing@126.com",{"name":56,"role":52,"phone":57,"phoneExt":17,"email":58},"Rong Lin, MD","+86-0591-87981619","linrong1214@foxmail.com",[60],{"facility":61,"status":62,"city":63,"state":64,"zip":65,"country":66,"countryCode":67,"cosmosGeoPoint":68,"geoPoint":73,"contacts":74},"The First Affiliated Hospital of Fujian Medical University","RECRUITING","Fuzhou","Fujian","350005","China","CN",{"type":69,"coordinates":70},"Point",[71,72],119.30611,26.06139,{"lat":72,"lon":71},[75,76],{"name":48,"role":52,"phone":53,"phoneExt":17,"email":54},{"name":56,"role":52,"phone":57,"phoneExt":17,"email":58},{"type":78,"investigatorFullName":17,"investigatorTitle":17,"investigatorAffiliation":17,"oldNameTitle":17,"oldOrganization":17},"SPONSOR","100592634",false,"NCT06995976","Dosimetry and Preliminary Clinical Application Study of a Novel Probe Targeting CD73","Inclusion Criteria:\n\nSigned informed consent and be able to follow up.\n\nExclusion Criteria:\n\nPregnant or lactational women; who suffered from severe hepatic and renal insufficiency.",true,"ALL","18 Years","90 Years",{"count":89,"type":90},30,"ESTIMATED","INTERVENTIONAL",[93],"EARLY_PHASE1","As a new CD73-targeted PET radiotracer, 68Ga-dPNE, is promising as an excellent imaging agent applicable to various cancers. In this study, we observed the safety, biodistribution and radiation dosimetry of 68Ga-dPNE in human volunteers. Furthermover, we conducted a comparative analysis of 68Ga-dPNE and 18F-FDG imaging to assess both the radiation dosimetry and diagnostic efficacy of 68Ga-dPNE.",[96],"Malignant Tumour","2025-05-21",{"date":99,"type":100},"2025-05-30","ACTUAL",{"date":102,"type":100},"2025-03-01",{"date":104,"type":90},"2026-03-01",{"name":5,"class":6},1]